Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6616685 | 0.92 | MAPK1 (0.48) | OPRM1OPRD1SLC6A2DRD3CHRM1 | |
| SCHEMBL1574160 | 0.82 | CYP3A4 (0.34) | OPRM1OPRD1SLC6A2DRD3CHRM1 | |
| SCHEMBL8715080 | 0.82 | CYP3A4 (0.34) | OPRM1OPRD1SLC6A2DRD3CHRM1 | |
| SCHEMBL5965398 | 0.75 | AR (0.38) | MAPK1 | |
| SCHEMBL11051916 | 0.73 | LMNA (0.40) | OPRM1OPRD1SLC6A2DRD3CHRM1 | |
| SCHEMBL4667127 | 0.73 | LMNA (0.40) | OPRM1OPRD1SLC6A2DRD3CHRM1 | |
| SCHEMBL4351591 | 0.71 | MAPK1 (0.41) | MAPK1 | |
| SCHEMBL5071115 | 0.71 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL3301280 | 0.71 | SLC6A2 (0.38) | OPRM1OPRD1SLC6A2DRD3CHRM1 | |
| SCHEMBL20725546 | 0.68 | SLC6A2 (0.43) | OPRM1OPRD1SLC6A2DRD3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0042365-B1 | SALTS OF ENDO-8-METHYL-8-SYN-ALKYL-8-AZONIABICYCLO-(3.2.1)-OCTANE-3-ALKYLCARBOXYLATES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THEM | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1984-09-12 | — | — | EP | claimed |
| US-7459556-B2 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | SCHERING-PLOUGH LTD. (CH) | 2008-12-02 | — | — | US | disclosed |
| EP-1791838-A2 | PROCESS FOR PREPARING SUBSTITUTED 8-AZABICYCLO[3.2.1] OCTAN-3-OLS | Schering-Plough Ltd. (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006031788-A2 | PROCESS FOR PREPARING SUBSTITUTED 8-AZABICYCLO[3.2.1] OCTAN-3-OLS | SCHERING-PLOUGH LTD. (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058343-A1 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | SCHERING-PLOUGH LTD. (CH) | 2006-03-16 | — | — | US | disclosed |
| EP-0042365-B1 | SALTS OF ENDO-8-METHYL-8-SYN-ALKYL-8-AZONIABICYCLO-(3.2.1)-OCTANE-3-ALKYLCARBOXYLATES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THEM | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1984-09-12 | — | — | EP | disclosed |
| US-4411902-A | ANTISPASMODICS | VALEAS S.P.A. (IT) | 1983-10-25 | — | — | US | disclosed |
| EP-0042365-A1 | Salts of endo-8-methyl-8-syn-alkyl-8-azoniabicyclo-(3.2.1)-octane-3-alkylcarboxylates, process for their preparation and therapeutic compositions containing them | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1981-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058343-A1 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | ODC1, CYP2C8, OR10J3 | OPRM1 223/4885OPRD1 106/4885SLC6A2 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.